Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]
Discontinued
Reference number: GID-TA10525
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2023 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately early September 2023.